Adaptimmune Ther ADR (ADAP)

$0.06 +0.01 (10.89%)
Market Cap 13.39M
Revenue (ttm) 178.03M
Net Income (ttm) -70.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.77%
Debt to Equity Ratio -0.36
Volume 65,309,797
Avg Vol 47,279,547
Day's Range N/A - N/A
Shares Out 265.05M
Stochastic %K 80%
Beta 2.24
Analysts Hold
Price Target $0.89

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 12 3543 0000
Address:
60 Jubilee Avenue, Milton Park, Abingdon, United Kingdom
2theMoon94
2theMoon94 Sep. 13 at 9:53 AM
$ADAP short interest percentage isn’t available online?
0 · Reply
Jerry53
Jerry53 Sep. 13 at 7:58 AM
$ADAP
0 · Reply
Jerry53
Jerry53 Sep. 13 at 7:57 AM
$ADAP
0 · Reply
ibuywhaturselling
ibuywhaturselling Sep. 13 at 7:54 AM
$ADAP .10 premarket on Monday run it
0 · Reply
sullivan1
sullivan1 Sep. 13 at 12:53 AM
$ADAP Story Highlights Adaptimmune Therapeutics received a Nasdaq notice for falling below the $35 million market value requirement. The company has until March 10, 2026, to regain compliance or face potential delisting.
0 · Reply
SofritoKid1
SofritoKid1 Sep. 13 at 12:35 AM
$ADAP 3/20/26 .50¢ calls will print 🔥
0 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 11:57 PM
Over the weekend holds 💰🐺 $OPI $ATCH $ADAP $RAYA $CHEK Monday let’s go💵💵💵💵💵 All my followers are making bank 🏦 You all gonna be rich 🤑
3 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 11:52 PM
Into the close fire 🔥list🔥👀👀👀🐺 $OPI $ATCH $ADAP $RAYA $CHEK Monday let’s go💵💵💵💵💵 All my followers are making bank 🏦 You all gonna be rich 🤑
0 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 11:43 PM
After hours fire 🔥list🔥👀👀👀🐺 $ATCH $OPI $ADAP $RAYA $CHEK Monday let’s go💵💵💵💵💵 All my followers are making bank 🏦 You all gonna be rich 🤑
1 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 11:25 PM
After hours fire 🔥list🔥👀👀👀🐺 $ADAP $RAYA $ATCH $OPI $CHEK Stay tuned everyone 👀🐺 All my followers are making bank 🏦 You all gonna be rich 🤑
1 · Reply
Latest News on ADAP
Adaptimmune Reports Q2 Financial Results and Provides Business Update

Aug 13, 2025, 7:30 AM EDT - 4 weeks ago

Adaptimmune Reports Q2 Financial Results and Provides Business Update

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Jul 28, 2025, 7:30 AM EDT - 6 weeks ago

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript

May 13, 2025, 1:59 PM EDT - 4 months ago

Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript

Adaptimmune Reports Q1 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 4 months ago

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

May 7, 2025, 12:00 PM EDT - 4 months ago

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 12:10 PM EDT - 6 months ago

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 20, 2025, 7:00 AM EDT - 6 months ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Mar 12, 2025, 4:54 PM EDT - 6 months ago

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Jan 30, 2025, 4:00 PM EST - 8 months ago

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Jan 13, 2025, 8:00 AM EST - 8 months ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Dec 19, 2024, 7:30 AM EST - 9 months ago

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Dec 2, 2024, 4:00 PM EST - 10 months ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:48 PM EST - 10 months ago

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024, 4:05 PM EST - 10 months ago

Adaptimmune Reports Q3 2024 Financial and Business Updates

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Nov 13, 2024, 9:00 AM EST - 10 months ago

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Nov 5, 2024, 9:19 AM EST - 11 months ago

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Oct 31, 2024, 5:20 PM EDT - 11 months ago

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Adaptimmune to Participate in Two Bank Conferences this September

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Adaptimmune to Participate in Two Bank Conferences this September

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 11:42 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Reports Q2 2024 Financial and Business Updates

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

US FDA approves Adaptimmune's gene therapy for rare type of cancer

Aug 2, 2024, 9:20 AM EDT - 1 year ago

US FDA approves Adaptimmune's gene therapy for rare type of cancer

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Aug 1, 2024, 8:20 PM EDT - 1 year ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 3, 2024, 9:54 AM EDT - 1 year ago

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Jun 17, 2024, 2:05 PM EDT - 1 year ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Jun 3, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

May 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

GLPG

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

May 30, 2024, 4:01 PM EDT - 1 year ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

GLPG

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

May 15, 2024, 10:07 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

Adaptimmune Reports Q1 2024 Financial and Business Updates

May 15, 2024, 7:30 AM EDT - 1 year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

May 15, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

HTGC

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

May 1, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26, 2024, 11:00 AM EDT - 1 year ago

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Mar 27, 2024, 7:30 PM EDT - 1 year ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 9:29 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Mar 6, 2024, 7:00 AM EST - 1 year ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Feb 27, 2024, 8:00 AM EST - 1 year ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Feb 21, 2024, 4:00 PM EST - 1 year ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Jan 31, 2024, 4:44 PM EST - 1 year ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Jan 4, 2024, 7:37 AM EST - 1 year ago

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Dec 6, 2023, 7:00 AM EST - 1 year ago

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Adaptimmune Receives Transfer of IND for Lete-cel Program

Nov 29, 2023, 8:00 AM EST - 1 year ago

Adaptimmune Receives Transfer of IND for Lete-cel Program

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 11:45 AM EST - 2 years ago

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Adaptimmune Reports Third Quarter Financial Results and Business Update

Nov 8, 2023, 7:30 AM EST - 2 years ago

Adaptimmune Reports Third Quarter Financial Results and Business Update

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Nov 8, 2023, 7:05 AM EST - 2 years ago

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Oct 25, 2023, 8:06 AM EDT - 2 years ago

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

Oct 23, 2023, 4:15 AM EDT - 2 years ago

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

2theMoon94
2theMoon94 Sep. 13 at 9:53 AM
$ADAP short interest percentage isn’t available online?
0 · Reply
Jerry53
Jerry53 Sep. 13 at 7:58 AM
$ADAP
0 · Reply
Jerry53
Jerry53 Sep. 13 at 7:57 AM
$ADAP
0 · Reply
ibuywhaturselling
ibuywhaturselling Sep. 13 at 7:54 AM
$ADAP .10 premarket on Monday run it
0 · Reply
sullivan1
sullivan1 Sep. 13 at 12:53 AM
$ADAP Story Highlights Adaptimmune Therapeutics received a Nasdaq notice for falling below the $35 million market value requirement. The company has until March 10, 2026, to regain compliance or face potential delisting.
0 · Reply
SofritoKid1
SofritoKid1 Sep. 13 at 12:35 AM
$ADAP 3/20/26 .50¢ calls will print 🔥
0 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 11:57 PM
Over the weekend holds 💰🐺 $OPI $ATCH $ADAP $RAYA $CHEK Monday let’s go💵💵💵💵💵 All my followers are making bank 🏦 You all gonna be rich 🤑
3 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 11:52 PM
Into the close fire 🔥list🔥👀👀👀🐺 $OPI $ATCH $ADAP $RAYA $CHEK Monday let’s go💵💵💵💵💵 All my followers are making bank 🏦 You all gonna be rich 🤑
0 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 11:43 PM
After hours fire 🔥list🔥👀👀👀🐺 $ATCH $OPI $ADAP $RAYA $CHEK Monday let’s go💵💵💵💵💵 All my followers are making bank 🏦 You all gonna be rich 🤑
1 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 11:25 PM
After hours fire 🔥list🔥👀👀👀🐺 $ADAP $RAYA $ATCH $OPI $CHEK Stay tuned everyone 👀🐺 All my followers are making bank 🏦 You all gonna be rich 🤑
1 · Reply
Rolo2024
Rolo2024 Sep. 12 at 11:24 PM
$ADAP Last 40 minutes to make up some ground! Just bought 4K hopefully ADAP moves up a bit.
0 · Reply
cimaboy
cimaboy Sep. 12 at 11:12 PM
$RAYA $ADAP $ATCH $OPI $CHEK
0 · Reply
DayTraderBatman
DayTraderBatman Sep. 12 at 10:55 PM
$ADAP looks like a break out here will result in a move toward 10 or 11 cents.
0 · Reply
jmcglothern28
jmcglothern28 Sep. 12 at 10:53 PM
$ADAP $1.00 next
0 · Reply
Rmead78
Rmead78 Sep. 12 at 10:51 PM
$ADAP added 35,000 shares.
0 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 10:47 PM
After hours fire 🔥list🔥👀👀👀🐺 $RAYA $ATCH $ADAP $OPI $CHEK Stay tuned everyone 👀🐺 All my followers are making bank 🏦 You all gonna be rich 🤑
2 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 10:32 PM
After hours fire 🔥list🔥👀👀👀🐺 $ATCH $ADAP $OPI $RAYA $CHEK Stay tuned everyone 👀🐺 All my followers are making bank 🏦 You all gonna be rich 🤑
0 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 10:17 PM
After hours fire 🔥list🔥👀👀👀🐺 $RAYA $ADAP $ATCH $OPI $CHEK Stay tuned everyone 👀🐺 All my followers are making bank 🏦 You all gonna be rich 🤑
0 · Reply
MandM_Car2025
MandM_Car2025 Sep. 12 at 10:11 PM
$ADAP this can definitely soar to levels we haven’t seen if the feds cut the rates next week (very likely) this is exciting times
0 · Reply
walfofwallstreet
walfofwallstreet Sep. 12 at 10:01 PM
After hours fire 🔥list🔥👀👀👀🐺 $RAYA 💎 $ADAP $ATCH $OPI $IHT 🔥 Stay tuned everyone 👀🐺 All my followers are making bank 🏦 You all gonna be rich 🤑
1 · Reply
shord93
shord93 Sep. 12 at 9:45 PM
$ADAP truly no idea what this is but I just bought 85,000 shares
2 · Reply
Tank510
Tank510 Sep. 12 at 9:44 PM
$NXTT Guy’s I don’t know everyone’s dealing here, but there’s a 0.05 little place giving lunch money right now. $ADAP is the place, but do your own homework first, K
0 · Reply